NCT03018756View on ClinicalTrials.gov

Nebulized Fentanyl in Patients With Mild to Moderate Interstitial Lung Disease and Chronic Dyspnea

PHASE3CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

June 25, 2018

Study Completion Date

November 30, 2020

Conditions

Interstitial Lung Disease

Interventions

DRUG

Fentanyl Citrate

100 mcg fentanyl citrate will be inhaled via nebulizer.

DRUG

Placebo

0.9% saline solution will be inhaled via nebulizer

Trial Locations (1)

K7L 2V7

Respiratory Investigation Unit, Queen's University, Kingston

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Dr. Denis O'Donnell

OTHER